Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Synergistic effect of immune checkpoint blockade and anti-angiogenesis in cancer treatment
Authors
Keywords
Immune checkpoint inhibitor, PD-1, PD-L1, CTLA-4, VEGF, Anti-angiogenesis, TKI, Tumor immune microenvironment
Journal
Molecular Cancer
Volume 18, Issue 1, Pages -
Publisher
Springer Nature
Online
2019-03-30
DOI
10.1186/s12943-019-0974-6
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Fc Effector Function Contributes to the Activity of Human Anti-CTLA-4 Antibodies
- (2018) Frederick Arce Vargas et al. CANCER CELL
- Combined VEGF and PD-L1 blockade displays synergistic treatment effects in an autochthonous mouse model of small cell lung cancer
- (2018) Lydia Meder et al. CANCER RESEARCH
- Cancer immunotherapy beyond immune checkpoint inhibitors
- (2018) Julian A. Marin-Acevedo et al. Journal of Hematology & Oncology
- Lessons learned from the blockade of immune checkpoints in cancer immunotherapy
- (2018) Xiaolei Li et al. Journal of Hematology & Oncology
- Preliminary results for avelumab plus axitinib as first-line therapy in patients with advanced clear-cell renal-cell carcinoma (JAVELIN Renal 100): an open-label, dose-finding and dose-expansion, phase 1b trial
- (2018) Toni K Choueiri et al. LANCET ONCOLOGY
- Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges
- (2018) Dai Fukumura et al. Nature Reviews Clinical Oncology
- Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
- (2018) Mark A. Socinski et al. NEW ENGLAND JOURNAL OF MEDICINE
- Targeting the IDO1 pathway in cancer: from bench to bedside
- (2018) Ming Liu et al. Journal of Hematology & Oncology
- Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors
- (2018) Ming Yi et al. Molecular Cancer
- Immunomodulation of Tumor Vessels: It Takes Two to Tango
- (2018) Anna Johansson-Percival et al. TRENDS IN IMMUNOLOGY
- Atezolizumab for the First-Line Treatment of Non-small Cell Lung Cancer (NSCLC): Current Status and Future Prospects
- (2018) Rachel Ryu et al. Frontiers in Oncology
- Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease
- (2018) Florence T. H. Wu et al. BRITISH JOURNAL OF CANCER
- Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study
- (2018) Jianming Xu et al. CLINICAL CANCER RESEARCH
- Developing combination strategies using PD-1 checkpoint inhibitors to treat cancer
- (2018) Emmett V. Schmidt Seminars in Immunopathology
- Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8+ T cells in the tumor microenvironment
- (2018) Yasuko Tada et al. Journal for ImmunoTherapy of Cancer
- PD-L1
- (2017) Anthousa Kythreotou et al. JOURNAL OF CLINICAL PATHOLOGY
- PD-1/PD-L blockade in gastrointestinal cancers: lessons learned and the road toward precision immunotherapy
- (2017) Junyu Long et al. Journal of Hematology & Oncology
- The next generation of immunotherapy: keeping lung cancer in check
- (2017) Ashwin Somasundaram et al. Journal of Hematology & Oncology
- The brain-penetrating CXCR4 antagonist, PRX177561, increases the antitumor effects of bevacizumab and sunitinib in preclinical models of human glioblastoma
- (2017) Giovanni Luca Gravina et al. Journal of Hematology & Oncology
- PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective
- (2017) Jun Wang et al. Journal of Hematology & Oncology
- Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
- (2017) Anthony B El-Khoueiry et al. LANCET
- Tumor angiogenesis revisited: Regulators and clinical implications
- (2017) Roberto Ronca et al. MEDICINAL RESEARCH REVIEWS
- Mutual regulation of tumour vessel normalization and immunostimulatory reprogramming
- (2017) Lin Tian et al. NATURE
- Tumour ischaemia by interferon-γ resembles physiological blood vessel regression
- (2017) Thomas Kammertoens et al. NATURE
- Dual angiopoietin-2 and VEGFA inhibition elicits antitumor immunity that is enhanced by PD-1 checkpoint blockade
- (2017) Martina Schmittnaegel et al. Science Translational Medicine
- Combined antiangiogenic and anti–PD-L1 therapy stimulates tumor immunity through HEV formation
- (2017) Elizabeth Allen et al. Science Translational Medicine
- Combined Anti-VEGF and Anti–CTLA-4 Therapy Elicits Humoral Immunity to Galectin-1 Which Is Associated with Favorable Clinical Outcomes
- (2017) Xinqi Wu et al. Cancer Immunology Research
- High Endothelial Venules and Other Blood Vessels: Critical Regulators of Lymphoid Organ Development and Function
- (2017) Ann Ager Frontiers in Immunology
- PD-L1 Expression, Tumor-infiltrating Lymphocytes, and Clinical Outcome in Patients With Surgically Resected Esophageal Cancer
- (2017) Taisuke Yagi et al. ANNALS OF SURGERY
- The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition
- (2016) P. S. Hegde et al. CLINICAL CANCER RESEARCH
- Expression of Vascular Endothelial Growth Factor in Ovarian Cancer Inhibits Tumor Immunity through the Accumulation of Myeloid-Derived Suppressor Cells
- (2016) Naoki Horikawa et al. CLINICAL CANCER RESEARCH
- The Complexity of Translating Anti-angiogenesis Therapy from Basic Science to the Clinic
- (2016) Weilan Ye DEVELOPMENTAL CELL
- Atezolizumab, an Anti–Programmed Death-Ligand 1 Antibody, in Metastatic Renal Cell Carcinoma: Long-Term Safety, Clinical Activity, and Immune Correlates From a Phase Ia Study
- (2016) David F. McDermott et al. JOURNAL OF CLINICAL ONCOLOGY
- Protein glycosylation in cancers and its potential therapeutic applications in neuroblastoma
- (2016) Wan-Ling Ho et al. Journal of Hematology & Oncology
- Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma
- (2016) Robert J. Motzer et al. ONCOLOGIST
- Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma
- (2016) Jeffrey J. Wallin et al. Nature Communications
- VEGF Neutralization Plus CTLA-4 Blockade Alters Soluble and Cellular Factors Associated with Enhancing Lymphocyte Infiltration and Humoral Recognition in Melanoma
- (2016) X. Wu et al. Cancer Immunology Research
- Angiopoietin-2 as a Biomarker and Target for Immune Checkpoint Therapy
- (2016) Xinqi Wu et al. Cancer Immunology Research
- VEGF-A/VEGFR2 signaling network in endothelial cells relevant to angiogenesis
- (2016) Chandran S. Abhinand et al. Journal of Cell Communication and Signaling
- Combining radiotherapy with sunitinib: lessons (to be) learned
- (2015) Esther A. Kleibeuker et al. ANGIOGENESIS
- Classifying Cancers Based on T-cell Infiltration and PD-L1
- (2015) Michele W.L. Teng et al. CANCER RESEARCH
- Targeting the tumor vasculature to enhance T cell activity
- (2015) Evripidis Lanitis et al. CURRENT OPINION IN IMMUNOLOGY
- Axitinib: A Review in Advanced Renal Cell Carcinoma
- (2015) Gillian M. Keating DRUGS
- VEGF-A modulates expression of inhibitory checkpoints on CD8+T cells in tumors
- (2015) Thibault Voron et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients
- (2015) Emanuela Romano et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Understanding high endothelial venules: Lessons for cancer immunology
- (2015) Ann Ager et al. OncoImmunology
- Antiangiogenesis Strategies Revisited: From Starving Tumors to Alleviating Hypoxia
- (2014) Rakesh K. Jain CANCER CELL
- Glycosylation-Dependent Lectin-Receptor Interactions Preserve Angiogenesis in Anti-VEGF Refractory Tumors
- (2014) Diego O. Croci et al. CELL
- Bevacizumab: A Review of Its Use in Advanced Cancer
- (2014) Gillian M. Keating DRUGS
- Tie1 deletion inhibits tumor growth and improves angiopoietin antagonist therapy
- (2014) Gabriela D’Amico et al. JOURNAL OF CLINICAL INVESTIGATION
- PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation
- (2014) Muhammad Zaeem Noman et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors
- (2014) Gregory T Motz et al. NATURE MEDICINE
- Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies
- (2014) Andrew J.S. Furness et al. TRENDS IN IMMUNOLOGY
- T-Cell and NK-Cell Infiltration into Solid Tumors: A Key Limiting Factor for Efficacious Cancer Immunotherapy
- (2014) I. Melero et al. Cancer Discovery
- Role of Angiopoietin-2 in Adaptive Tumor Resistance to VEGF Signaling Blockade
- (2014) Nicolò Rigamonti et al. Cell Reports
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Vascular Normalization as an Emerging Strategy to Enhance Cancer Immunotherapy
- (2013) Y. Huang et al. CANCER RESEARCH
- Unraveling galectin-1 as a novel therapeutic target for cancer
- (2013) Lucile Astorgues-Xerri et al. CANCER TREATMENT REVIEWS
- Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effectin vivo
- (2013) S. Yasuda et al. CLINICAL AND EXPERIMENTAL IMMUNOLOGY
- Cancer immunotherapy strategies based on overcoming barriers within the tumor microenvironment
- (2013) Thomas F Gajewski et al. CURRENT OPINION IN IMMUNOLOGY
- Oncology Meets Immunology: The Cancer-Immunity Cycle
- (2013) Daniel S. Chen et al. IMMUNITY
- Development and characterization of a high-throughput in vitro cord formation model insensitive to VEGF inhibition
- (2013) Beverly L Falcon et al. Journal of Hematology & Oncology
- VEGFA and tumour angiogenesis
- (2013) L. Claesson-Welsh et al. JOURNAL OF INTERNAL MEDICINE
- VEGFR and Type-V RTK Activation and Signaling
- (2013) M. Shibuya Cold Spring Harbor Perspectives in Biology
- Pericyte Depletion Results in Hypoxia-Associated Epithelial-to-Mesenchymal Transition and Metastasis Mediated by Met Signaling Pathway
- (2012) Vesselina G. Cooke et al. CANCER CELL
- Local Delivery of lnterleukin-12 Using T Cells Targeting VEGF Receptor-2 Eradicates Multiple Vascularized Tumors in Mice
- (2012) D. Chinnasamy et al. CLINICAL CANCER RESEARCH
- Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity
- (2012) Suzanne L Topalian et al. CURRENT OPINION IN IMMUNOLOGY
- Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy
- (2012) Weijing Sun Journal of Hematology & Oncology
- Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy
- (2012) Y. Huang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Selective Effects of PD-1 on Akt and Ras Pathways Regulate Molecular Components of the Cell Cycle and Inhibit T Cell Proliferation
- (2012) N. Patsoukis et al. Science Signaling
- Ipilimumab: An Anti-CTLA-4 Antibody for Metastatic Melanoma
- (2011) E. J. Lipson et al. CLINICAL CANCER RESEARCH
- An Antibody Targeted to VEGFR-2 Ig Domains 4-7 Inhibits VEGFR-2 Activation and VEGFR-2-Dependent Angiogenesis without Affecting Ligand Binding
- (2011) J. Kendrew et al. MOLECULAR CANCER THERAPEUTICS
- Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells
- (2011) Andrea Facciabene et al. NATURE
- Different Tumor Microenvironments Contain Functionally Distinct Subsets of Macrophages Derived from Ly6C(high) Monocytes
- (2010) K. Movahedi et al. CANCER RESEARCH
- Neogenesis and development of the high endothelial venules that mediate lymphocyte trafficking
- (2010) Haruko Hayasaka et al. CANCER SCIENCE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
- (2009) John M.L. Ebos et al. CANCER CELL
- Antiangiogenic Therapy Elicits Malignant Progression of Tumors to Increased Local Invasion and Distant Metastasis
- (2009) Marta Pàez-Ribes et al. CANCER CELL
- Sorafenib in Advanced Hepatocellular Carcinoma
- (2008) Josep M. Llovet et al. NEW ENGLAND JOURNAL OF MEDICINE
- Tumor Angiogenesis
- (2008) Robert S. Kerbel NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started